CELULARITY INC

Celularity (CELU) restores Nasdaq compliance, refocuses on placental‑derived cell therapies, and navigates market volatility with new financial discipline and pipeline acceleration.

Celularity Inc. (CELU) dips 19% as it seeks funding to push placental‑derived NK, CAR‑T, and stromal cell therapies forward. Find the latest trading, earnings and pipeline insights.

Celularity (CELU) surges 8.6% to $1.02, spotlighting its off‑the‑shelf placental cell therapies for oncology and infectious diseases.